Work

CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer

Year: 2015

Type: article

Source: Breast Cancer Research and Treatment

DOI: 10.1007/s10549-015-3349-8

Authors: Sarah J. Conley, Trenton L. Baker, Joseph P. Burnett, Rebecca L. Theisen, Douglas Lazarus, Christian G. Peters, Shawn G. Clouthier, Scott Eliasof, Max S. Wicha

Institutions: University of Michigan, Cerulean Pharma (United States)

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: OncoMed Pharmaceutical, China Scholarship Council

OpenAlex ID: W1971026321

FWCI: 3.155

Cites: 28

Cited by: 69

Related to: 10